These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25143359)

  • 41. Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.
    Schinkel JK; Zahm SH; Jatoi I; McGlynn KA; Gallagher C; Schairer C; Shriver CD; Zhu K
    Cancer Causes Control; 2014 Aug; 25(8):959-68. PubMed ID: 24839049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
    Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
    Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China.
    Xing P; Li J; Jin F
    Med Oncol; 2010 Sep; 27(3):926-31. PubMed ID: 19771534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
    Roseland ME; Schwartz K; Ruterbusch JJ; Lamerato L; Krajenta R; Booza J; Simon MS
    Breast Cancer Res Treat; 2017 Aug; 165(1):163-168. PubMed ID: 28547656
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases.
    Gapstur SM; Dupuis J; Gann P; Collila S; Winchester DP
    Cancer; 1996 Apr; 77(8):1465-71. PubMed ID: 8608530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data.
    Runnak MA; Hazha MA; Hemin HA; Wasan AA; Rekawt RM; Michael HD
    BMC Womens Health; 2012 Jun; 12():16. PubMed ID: 22727195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium.
    Bandera EV; Chandran U; Hong CC; Troester MA; Bethea TN; Adams-Campbell LL; Haiman CA; Park SY; Olshan AF; Ambrosone CB; Palmer JR; Rosenberg L
    Breast Cancer Res Treat; 2015 Apr; 150(3):655-66. PubMed ID: 25809092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
    Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
    J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence, mortality and receptor status of breast cancer in African Caribbean women: Data from the cancer registry of Guadeloupe.
    Deloumeaux J; Gaumond S; Bhakkan B; Manip M'Ebobisse N; Lafrance W; Lancelot P; Vacque D; Negesse Y; Diedhiou A; Kadhel P
    Cancer Epidemiol; 2017 Apr; 47():42-47. PubMed ID: 28119121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Pooled Case-only Analysis of Reproductive Risk Factors and Breast Cancer Subtype Among Black Women in the Southeastern United States.
    Sanderson M; Pal T; Beeghly-Fadiel A; Fadden MK; Dujon SA; Clinton C; Jimenez C; Davis J; Fortune M; Thompson J; Benson K; Conley N; Reid S; Tezak A; Shu XO; Zheng W; Blot WJ; Lipworth L
    Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1416-1423. PubMed ID: 33947654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy.
    Wright JL; Reis IM; Zhao W; Panoff JE; Takita C; Sujoy V; Gomez CR; Jorda M; Franceschi D; Hurley J
    Breast; 2012 Jun; 21(3):276-83. PubMed ID: 22178596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Occurrence of breast cancer subtypes in adolescent and young adult women.
    Keegan TH; DeRouen MC; Press DJ; Kurian AW; Clarke CA
    Breast Cancer Res; 2012 Mar; 14(2):R55. PubMed ID: 22452927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.
    Micello D; Marando A; Sahnane N; Riva C; Capella C; Sessa F
    Virchows Arch; 2010 Oct; 457(4):467-76. PubMed ID: 20809337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
    Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
    Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
    Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.